You are here

Inotuzumab Ozogamicin Scores in Pivotal ALL Study

Treatment extends survival compared with standard chemotherapy

Positive results have been reported from a phase 3, open-label, randomized study evaluating the safety and efficacy of inotuzumab ozogamicin (Pfizer/UCB) compared with investigator-choice chemotherapy in 326 adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). The findings showed improvement over chemotherapy on a number of measures, including complete hematologic remission and progression-free survival (PFS). The data were published in the New England Journal of Medicine.

Inotuzumab ozogamicin is an investigational antibody–drug conjugate consisting of a monoclonal antibody targeting CD22, a cell-surface antigen found on cancer cells, linked to a cytotoxic agent, calicheamicin. When inotuzumab ozogamicin binds to the CD22 antigen on malignant B-cells, it is thought to be internalized into the cell, where the calicheamicin is released to destroy the cell.

The INO-VATE ALL trial had two independent primary endpoints: a complete response with or without hematologic remission and OS. The study met its first primary endpoint of a complete response, which was significantly better with inotuzumab ozogamicin compared with chemotherapy (80.7% vs. 29.4%, respectively; P < 0.001). Inotuzumab ozogamicin also significantly extended PFS compared with chemotherapy (hazard ratio [HR], 0.45; median PFS, 5.0 vs. 1.8 months, respectively; P < 0.001).

The second primary endpoint of OS showed a strong trend toward longer OS for patients treated with inotuzumab ozogamicin compared with chemotherapy but did not reach statistical significance (HR, 0.77; median OS, 7.7 months vs. 6.7 months, respectively; P = 0.0203). The two-year OS rate for inotuzumab ozogamicin was 23% compared with 10% for chemotherapy.

The results from the INO-VATE ALL trial also showed that 78.4% of patients treated with inotuzumab ozogamicin achieved minimal residual disease (MRD) negativity (78.4%) and experienced a duration of response (DOR) of 4.6 months (HR, 0.55). In comparison, 28.1% (P < 0.001) of patients treated with chemotherapy achieved MRD negativity, and the median DOR was 3.1 months (P < 0.034). Moreover, more patients proceeded to stem-cell transplant with inotuzumab ozogamicin compared with standard chemotherapy (41% vs. 11%; P < 0.001).

The most common adverse events (AEs) associated with both inotuzumab ozogamicin and chemotherapy were cytopenias, including febrile neutropenia (16% vs. 22%). Common nonhematologic treatment-emergent adverse events with inotuzumab ozogamicin included nausea (32%), headache (28%), and pyrexia (27%). Patients in the chemotherapy arm experienced nausea (47%), pyrexia (43%), and diarrhea (40%).

Veno-occlusive liver disease (VOD) of any grade occurred more often in patients treated with inotuzumab ozogamicin compared with those given chemotherapy (11% vs. 1%). Five patients taking inotuzumab ozogamicin developed VOD during treatment, and 10 patients developed VOD after subsequent stem-cell transplant. Among those taking chemotherapy, one patient developed VOD after transplant; no cases of VOD occurred during treatment with chemotherapy.

Inotuzumab ozogamicin received a breakthrough therapy designation from the FDA for the treatment of ALL in October 2015. ALL is an aggressive type of leukemia with a poor prognosis in adults. The current foundational treatment is intensive, long-term chemotherapy. It has been estimated that 6,590 cases of ALL will be diagnosed in the United States in 2016, with approximately two in five cases in adults. Approximately 20% to 40% of newly diagnosed adults with ALL are cured with current treatment regimens. For adult patients with relapsed or refractory ALL, the five-year overall survival rate is less than 10%.

Source: Pfizer; June 12, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks